Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Mit dieser Aktie könntest Du von der Cannabis-Legalisierungswelle profitieren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0HG6G | ISIN: SE0000736415 | Ticker-Symbol: C5G
Frankfurt
22.05.24
09:17 Uhr
1,790 Euro
-0,086
-4,58 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
OREXO AB Chart 1 Jahr
5-Tage-Chart
OREXO AB 5-Tage-Chart
RealtimeGeldBriefZeit
1,8181,92422.05.
PR Newswire
783 Leser
Artikel bewerten:
(2)

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

UPPSALA, Sweden, May 10, 2024 /PRNewswire/ -- On March 28, 2024, Orexo AB (publ), ("Orexo" or the "Company") (STO: ORX) (OTCQX: ORXOY) successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years (the "Bonds").

Pursuant to the terms and conditions for the Bonds, Orexo has undertaken to apply for admission to trading of the Bonds on the sustainable bond list of Nasdaq Stockholm. For this purpose, the Company has prepared a listing prospectus, which today has been approved by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The prospectus is available at the Company's website www.orexo.com and at the Swedish Financial Supervisory Authority's website www.fi.se. The application for admission to trading has been submitted and the first day of trading of the Bonds is estimated to be around May 14, 2024.

For further information please contact:
Nikolaj Sørensen, President and CEO
Fredrik Järrsten, EVP and CFO
Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com

About Orexo
Orexo is a Swedish pharmaceutical company with over 25 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2023 amounted to SEK 639 million, and the number of employees to 116. Orexo is listed on Nasdaq Stockholm's main list and is available as an ADR on OTCQX (ORXOY) in the US.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.

The information was sent for publication, through the agency of the contact person set out above, on May 10, 2024, at 1.30 pm CET.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/orexo/r/orexo-publishes-prospectus-and-applies-for-admission-to-trading-of-social-bonds-on-nasdaq-stockholm,c3976889

The following files are available for download:

https://mb.cision.com/Main/694/3976889/2788792.pdf

Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm

Cision View original content:https://www.prnewswire.co.uk/news-releases/orexo-publishes-prospectus-and-applies-for-admission-to-trading-of-social-bonds-on-nasdaq-stockholm-302142316.html

KI-Champions: 3 Top-Werte, die Ihr Portfolio revolutionieren
Fordern Sie jetzt den brandneuen kostenfreien Sonderreport an und erfahren Sie, wie Sie von den enormen Wachstumschancen im Bereich Künstliche Intelligenz profitieren können - 100 % kostenlos.
Hier klicken
© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.